Use the hyperlinks, where available to access additional clinical trial information.
An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
The study will consist of two cohorts, broadly, cohort A - patients without a pathogenic BRCA1 or BRCA2 mutation but with other germline or somatic mutations in other HRD genes; cohort B- patients with a pathogenic BRCA1 or BRCA2. All participants will receive a combined treatment of pamiparib and tislelizumab. Pampiparib will be administered orally, twice daily, at a dose of 40mg. Tislelizumab will be administered intravenously, every 21 days, at a dose of 200mg.